Now showing items 1-5 of 5

    • Classical Zariski pairs 

      Akyol, A. (2012)
      We enumerate and classify up to equisingular deformation all irreducible plane sextics constituting the so called classical Zariski pairs. In most cases we obtain two deformation families, called abundant and non-abundant. ...
    • Geography of irreducible plane sextics 

      Akyol, A.; Degtyarev, A. (Wiley, 2015)
      We complete the equisingular deformation classification of irreducible singular plane sextic curves. As a by-product, we also compute the fundamental groups of the complement of all but a few maximizing sextics.
    • A highly potent TACC3 inhibitor as a novel anticancer drug candidate 

      Akbulut, Özge; Lengerli, D.; Saatci, Özge; Duman, Elif; Şeker, Urartu Özgür Şafak; Işık, A.; Akyol, A.; Çalışkan, B.; Banoğlu, E.; Şahin, Özgür (NLM (Medline), 2020)
      TACC3, a transforming acidic coiled-coil (TACC) family member, is frequently upregulated in a broad spectrum of cancers, including breast cancer. It plays critical roles in protecting microtubule stability and centrosome ...
    • Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer 

      Saatçi, Ö.; Kaymak, A.; Raza, Umar; Ersan, Pelin G.; Akbulut, Özge; Banister, C. E.; Sikirzhytski, V.; Tokat, Ünal Metin; Aykut, Gamze; Ansari, Suhail A.; Tatlı-Doğan, H.; Doğan, M.; Jandaghi, P.; Işık, A.; Gündoğdu, F.; Kösemehmetoğlu, K.; Dizdar, Ö.; Aksoy, S.; Akyol, A.; Üner, A.; Buckhaults, P. J.; Riazalhosseini, Y.; Şahin, Özgür (Nature Research, 2020)
      Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance ...
    • Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer 

      Saatçi, Özge; Borgoni, S.; Akbulut, Özge; Durmuş, Selvi; Raza, Umar; Eyüpoğlu, Erol; Alkan, Can; Akyol, A.; Kütük, Ö.; Wiemann, S.; Şahin, Özgür (Nature Publishing Group, 2018)
      Trastuzumab-refractory, HER2 (human epidermal growth factor receptor 2)-positive breast cancer is commonly treated with trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the microtubule-targeting ...